| Frontiers in Oncology | |
| Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer | |
| Oncology | |
| Patrick J. Lewicki1  Christopher E. Barbieri1  Jim C. Hu1  Bashir Al Hussein Al Awamlh1  Spyridon P. Basourakos1  Siv Venkat1  Michael Tzeng1  Jonathan E. Shoag2  Michael A. Gorin3  Krishnan Patel4  | |
| [1] Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, United States;Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, United States;Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States;Department of Urology, University of Pittsburg School of Medicine, Pittsburgh, PA, United States;Urology Associates and UPMC Western Maryland, Cumberland, MD, United States;Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, United States; | |
| 关键词: prostate cancer; tissue biomarker; prognosis; genetic marker; decision making; | |
| DOI : 10.3389/fonc.2021.676716 | |
| received in 2021-03-05, accepted in 2021-04-21, 发布年份 2021 | |
| 来源: Frontiers | |
PDF
|
|
【 摘 要 】
Risk stratification of men with clinically localized prostate cancer has historically relied on basic clinicopathologic parameters such as prostate specific antigen level, grade group, and clinical stage. However, prostate cancer often behaves in ways that cannot be accurately predicted by these parameters. Thus, recent efforts have focused on developing tissue-based genomic tests that provide greater insights into the risk of a given patient’s disease. Multiple tests are now commercially available and provide additional prognostic information at various stages of the care pathway for prostate cancer. Indeed, early evidence suggests that these assays may have a significant impact on patient and physician decision-making. However, the impact of these tests on oncologic outcomes remains less clear. In this review, we highlight recent advances in the use of tissue-based biomarkers in the treatment of prostate cancer and identify the existing evidence supporting their clinical use.
【 授权许可】
Unknown
Copyright © 2021 Basourakos, Tzeng, Lewicki, Patel, Al Hussein Al Awamlh, Venkat, Shoag, Gorin, Barbieri and Hu
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202310100468519ZK.pdf | 336KB |
PDF